Best Practices for the Management of Neuroendocrine Tumors

A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.

Experts in the management of NETs discuss how the treatment landscape has evolved.

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.

The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, review the differences among the somatostatin analogues, particularly the differences in PK data.

The panel of experts discuss how they choose 1 somatostatin analogue over another and the factors to consider in the management of NETs.

Megan May, PharmD, BCOP, and Cecilia Lau, RPh, BCOP, APh, discuss the pharmacists’ role in choosing the treatment plan for patients with NETs.

Experts in the management of NETs review the various delivery systems and preparations available for short- and long-acting somatostatin analogues.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss the availability of home-injection programs for patients with NETs, especially during the coronavirus pandemic.

Cecilia Lau, RPh, BCOP, APh, reviews the efficacy and safety data for everolimus in the treatment of NETs.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, discuss the management of stomatitis caused by everolimus when used for NETs.

A panel of experts in the management of NETs discuss the role of peptide receptor radionuclide therapy for NETs.

Experts in the management of NETs share the challenges of getting therapeutic agents on the formulary.

Megan May, PharmD, BCOP, reviews the authorization process for treatment options for the management of NETs.

A panel of experts in neuroendocrine tumors review the challenges in the management of patients based on the site of the tumor.

Megan May, PharmD, BCOP, Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, share their thoughts on unmet needs in the management of neuroendocrine tumors.